- Home
- LUCD vs MBOT Comparison
LUCD vs MBOT Comparison
Compare LUCD & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | MBOT |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.4M | 134.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LUCD | MBOT |
|---|---|---|
| Price | $1.20 | $2.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $3.94 | ★ $8.75 |
| AVG Volume (30 Days) | 599.8K | ★ 1.4M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,399,000.00 | N/A |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $147.43 | $3,119.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.01 | N/A |
| 52 Week Low | $0.80 | $1.25 |
| 52 Week High | $1.80 | $4.67 |
Technical Indicators
Market Signals| Indicator | LUCD | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 48.61 |
| Support Level | $1.12 | $2.06 |
| Resistance Level | $1.24 | $2.22 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 78.09 | 70.37 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About MBOT Microbot Medical Inc.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.